Antibacterial Therapy of Patients With COVID-19 During The Outpatient and Hospital Stages

Although antibiotics (AB) are ineffective for the treatment of COVID-19, they are often prescribed to patients with the novel coronavirus infection (NCV) for a variety of reasons. They include the difficulty of excluding bacterial co-infection at the first contact with the patient, as well as the possibility of developing a secondary bacterial infection. The aim  of the work is to assess the frequency and background of prescribing antibiotics to hospitalized patients with confirmed COVID-19. Material and methods. A retrospective analysis of 160 hospital records of patients with confirmed COVID-19, who were treated in various Infectious Diseases Departments during the period from September to October 2020, was carried out. The selection was done by the method of random sampling. The analysis did not include the records of patients admitted to the ICU for NCV. Results. Information about the appointment of antibacterial drugs before hospitalization was found in 109 patients, of which only 51 patients did not receive AB on an outpatient basis. The remaining 58 (53.2%) patients began taking ABs on their own or based on the recommendation of an outpatient doctor, including 31 patients who took two or more drugs (successively or simultaneously). The most commonly used antibiotics were: macrolides (37 patients), cephalosporins (24 patients), respiratory fluoroquinolones (12 patients), and aminopenicillins (5 patients). On admission, AB was prescribed for almost all patients, except for one. The most frequently prescribed antibiotics were: macrolides (61%), mainly azithromycin, and respiratory fluoroquinolones (54.1%), mainly levofloxacin. In most cases, these drugs were combined with 3^rd or 4^th generation cephalosporins. Most patients received more than one AB: two drugs were prescribed to 86 (54.1%) patients, three — to 34 (21.4%) patients. AB therapy was carried out for a long time: the maximum number of days for macrolide administration (excluding previous AB therapy at the outpatient stage) was 16 days, respiratory fluoroquinolones — 22 days,3^rd generation cephalosporins — 19 days,4^th generation cephalosporins — 17 days, carbapenems — 34 days. In almost 100% of cases, ABs were prescribed on the first day of admission of patients, and their therapy continued until the patient was discharged from the hospital. Conclusion. The appointment of antibiotics at the hospital stage was established for the vast majority of patients in the absence of clear indications for their appointment. Such a frequent prescription of antibiotics is accompanied by a number of problems: immediate – side effects of such therapy (for example, antibiotic-associated diarrhea), long-term — an increase in antibiotic resistance of microorganisms.

1. Bakaletz L.O. Viral-bacterial co-infections in the respiratory tract. Curr Opin Microbiol. 2017; 35: 30–35. doi: 10.1016/j.mib.2016.11.003.

2. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M. et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020; 71: 2459–2468. doi: 10.1093/cid/ciaa530.

3. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020; 81: 266–275. doi: 10.1016/j.jinf.2020.05.046.

4. Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFadden D.R. et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020; 26: 1622–1629. doi: 10.1016/j.cmi.2020.07.016.

5. Rawson T.M., Moore L.S.P., Castro-Sanchez E., Charani E., Davies F., Satta G.et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020; 75: 1681–1684. doi: 10.1093/jac/dkaa194.

6. Huttner B., Catho G., Pano-Pardo J.R., Pulcini C., Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020; 26: 808–810. doi: 10.1016/j.cmi.2020.04.024.

7. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiya 11 (07.05.2021). Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/BМР_COVID-19.pdf. Accessed: August 18, 2021. (in Russian)

8. Owens R.C. Jr., Nolin T.D. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006; 43 (12): 1603–1611. doi: 10.1086/508873.

9. Ray W.A., Murray K.T., Hall K., Arbogast P.G., Stein C.M. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366 (20): 1881–1890. doi: 10.1056/NEJMoa1003833.

10. Rao G.A., Mann J.R., Shoaibi A., Bennett C.L., Nahhas G., Sutton S.S. et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014; 12 (2): 121–127. doi: 10.1370/afm.1601.

11. Lu Z.K., Yuan J., Li M., Sutton S.S., Rao G.A., Jacob S., Bennett C.L. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf. 2015; 14 (2): 295–303. doi: 10.1517/14740338.2015.989210.

12. Informatsionnoe pis'mo MASRM COVID-19: obsuzhdenie spornykh momentov, kasayushchikhsya vyzvannykh koronaviru-som izmenenii v legkikh, i podkhodov k lecheniyu. 2020. Available at: http://www.antibiotic.ru/index.php?article=2959. Accessed: August 18, 2021. (in Russian)

13. Nieuwlaat R.,Mbuagbaw L.,Mertz D.,Burrows L.,Bowdish D.M.E.,Moja L. et al. COVID-19 and antimicrobial resistance: parallel and interacting health emergencies. Clin Infect Dis. 2021;72 (9): 1657–1659. doi: 10.1093/cid/ciaa773.

14. Van Duin D., Barlow G., Nathwani D. The impact of the COVID-19 pandemic on antimicrobial resistance: a debate. JAC-Antimicrob Resist. 2020; 2 (3): dlaa053. doi: 10.1093/jacamr/dlaa053.

15. Westblade L.F., Simon M.S., Satlin M.J. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol. 2021:S0966-842X(21)00094-9. doi: 10.1016/j.tim.2021.03.018.

16. Chen S.,Zhu Q.,Xiao Y.,Wu C.,Jiang Z.,Liu L.,Qu J. Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study. Clin Respir J. 2021; 15 (7): 815–825. doi: 10.1111/crj.13369.

17. Russell C.D., Fairfield C.J., Drake T.M., Turtle L., Seaton R.A., Wootton D.G. et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021; 2 (8): 354–365. doi: 10.1016/S2666-5247(21)00090-2.

18. Ruiz-Bastián M., Falces-Romero I., Ramos-Ramos J.C., de Pablos M., García-Rodríguez J. SARS-CoV-2 Working Group. Bacterial co-infections in COVID-19 pneumonia in a tertiary care hospital: Surfing the first wave. Diagn Microbiol Infect Dis. 2021; 101 (3): 115477. doi:10.1016/j.diagmicrobio.2021.115477.

19. Klein E.Y., Monteforte B., Gupta A., Jiang W., May L., Hsieh Y.H., Dugas A. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016; 10 (5): 394–403. doi: 10.1111/irv.12398.

20. Langford B.J., So M., Raybardhan S., Leung V., Soucy J.R., Westwood D. et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021; 27 (4): 520–531. doi: 10.1016/j.cmi.2020.12.018.

21. Could Efforts to Fight the Coronavirus Lead to Overuse of Antibiotics? [Internet] The Pew Charitable Trusts. Mar 2021. Available from: https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/03/could-efforts-to-fight-the-coronavirus-lead-to-overuse-of-antibiotics.

22. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. 2020. Available at: https://www.nice.org.uk/guidance/ng173/chapter/4-Assessing-the-ongoing-need-for-antibiotics. [Accessed: October 09, 2020].

23. Ghazi I.M., Nicolau D.P., Nailor M.D., Aslanzadeh J., Ross J.W., Kuti J.L. Antibiotic utilization and opportunities for stewardship among hospitalized patients with influenza respiratory tract infection. Infect Control Hosp Epidemiol. 2016; 37: 583–589. doi: 10.1017/ice.2016.17.

24. Karami Z., Knoop B.T., Dofferhoff A.S.M., Blaauw M.J.T., Janssen N.A., van Apeldoorn M. et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infectious Diseases. 2021; 53 (2): 102–110, doi: 10.1080/23744235.2020.1839672.

25. Rothe K., Feihl S., Schneider J., Wallnöfer F., Wurst M., Lukas M. et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. 2021; 40: 859–869. doi: 10.1007/s10096-020-04063-8.

26. Al-Kuraishy H.M., Al-Naimi M.S., Lungnier C.M., Al-Gareeb A.I. Macrolides and COVID-19: An optimum premise. Biomed Biotechnol Res J. 2020; 4: 189–192.

27. Mason J.W. Antimicrobials and QT prolongation. J Antimicrob Chemother. 2017; 72 (5):1272–1274. doi: 10.1093/jac/dkw591.